Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

Ouzama Nicholson; Fay DiCandilo; James G. Kublin; Xiao Sun; Erin Quirk; Michelle M. Miller; Glenda Gray; Jean W. Pape; Michael Robertson; Devan V. Mehrotra; Steven G. Self; Katherine Turner; Jorge Sánchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo R. Casimiro; Scott M. Hammer for the Merck V - HIV

doi:10.1089/aid.2010.0151

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

vp/dose groups. Data from this first international study indicate that adenovirus-vectored vaccines are well tolerated and may be immunogenic in subjects from regions with high prevalence of preexisting Ad5 immunity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nicholson et al. (2010) studied this question.

synapsesocial.com/papers/6a2294a3b95e3d1e36149b42 https://doi.org/10.1089/aid.2010.0151

View at Publisher

Ask AI

Bookmark

Share

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading